Bank of America Securities Remains a Sell on Ginkgo Bioworks Holdings (DNA)

In a report released yesterday, from Bank of America Securities maintained a Sell rating on Ginkgo Bioworks Holdings. The company’s shares closed yesterday at $8.95.

Meet Your ETF AI Analyst

• Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
• Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Currently, the analyst consensus on Ginkgo Bioworks Holdings is a Moderate Sell with an average price target of $11.50.

Based on Ginkgo Bioworks Holdings’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $49.6 million and a GAAP net loss of $60.3 million. In comparison, last year the company earned a revenue of $56.21 million and had a GAAP net loss of $217.18 million

Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DNA in relation to earlier this year. Most recently, in September 2025, Christian Henry, a Director at DNA sold 20,000.00 shares for a total of $219,800.00.